UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Investment analysts at HC Wainwright lifted their Q2 2025 earnings per share estimates for UroGen Pharma in a research report issued to clients and investors on Thursday, May 22nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.74) per share for the quarter, up from their previous forecast of ($0.75). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for UroGen Pharma's current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma's Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.95) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.45) EPS and FY2026 earnings at ($2.14) EPS.
URGN has been the subject of several other research reports. Scotiabank began coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price target for the company. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a report on Thursday, May 8th. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price on the stock. Guggenheim lowered their target price on shares of UroGen Pharma from $40.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, May 23rd. Finally, The Goldman Sachs Group decreased their price target on UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $27.43.
View Our Latest Report on URGN
UroGen Pharma Stock Down 5.0%
NASDAQ URGN traded down $0.20 during trading on Monday, reaching $3.77. 199,008 shares of the company's stock traded hands, compared to its average volume of 692,391. UroGen Pharma has a 12-month low of $3.42 and a 12-month high of $20.70. The firm has a market cap of $173.82 million, a price-to-earnings ratio of -1.21 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The company's 50 day simple moving average is $9.40 and its two-hundred day simple moving average is $10.44.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million.
Institutional Investors Weigh In On UroGen Pharma
Several institutional investors and hedge funds have recently made changes to their positions in URGN. Jane Street Group LLC increased its position in UroGen Pharma by 94.3% in the first quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock worth $566,000 after buying an additional 24,839 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in UroGen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock valued at $48,227,000 after purchasing an additional 2,983,368 shares during the period. Parkman Healthcare Partners LLC raised its stake in shares of UroGen Pharma by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company's stock valued at $4,348,000 after buying an additional 23,292 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of UroGen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock worth $258,000 after purchasing an additional 1,653 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in UroGen Pharma by 347.5% during the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company's stock worth $1,262,000 after acquiring an additional 88,577 shares during the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.
UroGen Pharma Company Profile
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Read More
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
